FDA has approved Millennium and Takeda’s Velcade (bortezomib) for previously untreated multiple myeloma. “This comes as wonderful news for patients. The VISTA trial showed a 30% complete remission rate with bortezomib(Drug information on bortezomib) compared to 4% for the control arm. Importantly, patients treated with bortezomib also experienced a survival benefit,” said Paul Richardson, MD, senior investigator for the study and clinical director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. For a report on the VISTA study, see ONI March 2008, page 51.